BMEA: Biomea Fusion, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
62 institutions reported holding $36.49M of Biomea Fusion, Inc. on Form 13F (65 the quarter before). 7 opened a new position and 13 sold out. Shares held by institutions: +3%.
| Largest holders | Shares | Value |
|---|---|---|
| FMR LLC | 8,814,946 | $12.96M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,829,927 | $4.16M |
| MARSHALL WACE, LLP | 2,049,802 | $3.01M |
| Aisling Capital Management LP | 2,048,757 | $3.01M |
| RENAISSANCE TECHNOLOGIES LLC | 1,455,474 | $2.14M |
| FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. | 723,176 | $1.06M |
| BlackRock, Inc. | 715,445 | $1.05M |
| GEODE CAPITAL MANAGEMENT, LLC | 708,854 | $1.04M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 612,735 | $901K |
| Mariner, LLC | 594,726 | $874K |
Clinical trial readouts
2 Phase 2 or 3 trials by Biomea Fusion, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-03 (est.) | icovamenib 100mg | Type 2 Diabetes | Phase 2 | 64 | Enrollment complete | NCT07502495 |
| 2027-06 (est.) | icovamenib 100 mg | Type 2 Diabetes | Phase 2 | 60 | Recruiting | NCT07502508 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.